Omeros (NASDAQ:OMER) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.55) by 14.55 percent. This is a 13.7 percent increase over losses of $(0.73) per share from the same period last year.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | $9.00 | Buy | Rodman & Renshaw |
| 12/8/2022 | $12.00 → $2.00 | Buy → Neutral | UBS |
| 11/8/2022 | $8.00 → $3.00 | Neutral → Underperform | BofA Securities |
| 6/8/2022 | $12.00 → $4.00 | Buy → Neutral | BofA Securities |
| 10/19/2021 | $19.00 → $12.00 | Buy | HC Wainwright & Co. |
| 10/8/2021 | Neutral → Underweight | JP Morgan | |
| 10/6/2021 | $32.00 → $19.00 | Buy | HC Wainwright & Co. |
| 10/4/2021 | Buy → Hold | Maxim Group |
Omeros Corporation (NASDAQ:OMER) today announced an update on its progress toward planned resubmission of its biologics license application ("BLA") for narsoplimab, the company's first-in-class antibody targeting MASP-2, the effector enzyme of the lectin pathway of complement, in hematopoietic stem cell transplant-associated thrombotic microangiopathy ("TA-TMA"). In last week's quarterly earnings release and associated call, Omeros stated that it was awaiting feedback from the U.S. Food and Drug Administration ("FDA") on the company's revised statistical analysis plan ("SAP") for the BLA. Omeros has now received FDA's response on the revised SAP, has no other presubmission information reque
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2024, which include: Net loss for the third quarter of 2024 was $32.2 million, or $0.56 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023. For the nine months ended September 30, 2024, net loss was $125.5 million, or $2.15 per share, compared to a net loss of $108.8 million, or $1.73 per share in the prior year period. At September 30, 2024, we had $123.2 million of cash and short-term investments available for operations and debt servicing,
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you wi
Rodman & Renshaw initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00
UBS downgraded Omeros from Buy to Neutral and set a new price target of $2.00 from $12.00 previously
BofA Securities downgraded Omeros from Neutral to Underperform and set a new price target of $3.00 from $8.00 previously
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2024, which include: Net loss for the third quarter of 2024 was $32.2 million, or $0.56 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023. For the nine months ended September 30, 2024, net loss was $125.5 million, or $2.15 per share, compared to a net loss of $108.8 million, or $1.73 per share in the prior year period. At September 30, 2024, we had $123.2 million of cash and short-term investments available for operations and debt servicing,
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you wi
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, as well as cancers and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2024, which include: Net loss for the second quarter of 2024 was $56.0 million, or $0.97 per share, compared to a net loss of $37.3 million, or $0.59 per share for the second quarter of 2023.
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
10-Q - OMEROS CORP (0001285819) (Filer)
8-K - OMEROS CORP (0001285819) (Filer)
10-Q - OMEROS CORP (0001285819) (Filer)
Needham analyst Serge Belanger reiterates Omeros (NASDAQ:OMER) with a Hold.
$118.1 million, or 55%, of outstanding convertible notes due in 2026 repurchased at approximately 75% of notional value, resulting in $51 million in total debt extinguishmentRepurchase funded from new $67 million secured four-year term loan maturing in June 2028 together with $21 million cash on handCredit facility includes $25 million delayed draw term loan conditionally available to fund narsoplimab commercializationTransactions include no equity component, preventing shareholder dilution, and enable additional debt reduction
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 0.1% on Thursday. The Dow traded up 0.01% to 39,912.06 while the NASDAQ fell 0.10% to 16,726.17. The S&P 500 also fell, dropping, 0.04% to 5,306.04. Check This Out: Oklo Is ‘Too Risky,’ Jim Cramer Says: Buy This General Electric Spinoff Instead Leading and Lagging SectorsConsumer staples shares rose by 1.7% on Thursday. In trading on Thursday, materials shares fell by 0.5%. Top Headline Deere & Co (NYSE:DE) reported upbeat second-quarter earnings, but lowered its net income 2024 outlook. The company's net sales and revenue declined 12% year-over-year to $15.235 billion, beating
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G - OMEROS CORP (0001285819) (Subject)
3 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
Omeros Corporation (NASDAQ:OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader, Dr. Grauer brings to Omeros over 20 years of industry experience across a broad range of therapeutic areas including inflammation, nephrology, oncology, neurology, endocrinology, and metabolism. "We are very pleased to welcome Andreas to Omeros' leadership team," said Gregory A. Demopulos, M.D., chairman and ch